Related Experiment Video
Updated: Jun 26, 2026
10:09
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Cdc7 as a potential new target for cancer therapy
Sayuri Ito1, Chika Taniyami, Naoko Arai
1Genome Dynamics Project, Tokyo Metropolitan Institute of Medical Science, Bunkyo-ku, Tokyo, Japan.
Drug News & Perspectives
|January 31, 2009
Summary
Cdc7 kinase is essential for DNA replication and fork stability. Inhibiting this kinase causes cancer cell death, making it a promising new cancer therapy target.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- Cdc7 kinase is vital for DNA replication origin firing and replication fork maintenance.
- Inactivation of Cdc7 kinase leads to replication fork destabilization, genomic instability, and cell death, particularly in cancer cells.
Purpose of the Study:
- To investigate the role of Cdc7 kinase in DNA replication and genomic stability.
- To evaluate Cdc7 kinase as a potential therapeutic target for cancer treatment.
Main Methods:
- The study likely involved molecular biology techniques to assess Cdc7 kinase function and its impact on DNA replication.
- Investigated the effects of Cdc7 inhibition on cancer cell viability and tumor growth in preclinical models.
Main Results:
- Cdc7 kinase inactivation results in destabilized replication forks and acute genomic instability.
- Cancer cells exhibit preferential cell death upon Cdc7 inactivation.
- Early-stage Cdc7 inhibitors have demonstrated efficacy in delaying tumor growth in animal models.
Conclusions:
- Cdc7 kinase is a critical regulator of DNA replication and genomic integrity.
- Cdc7 kinase represents a promising novel therapeutic target for cancer treatment.
- Cdc7 inhibitors show potential for delaying tumor progression.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...